1. What is the Chemxpert database?

Chemxpert database is a techno-commercial information platform developed and operated by Lifescience Intellipedia Pvt. Ltd. Our data provides valuable insights regarding sourcing, marketing, development, and regulatory functions for the entire Lifescience industry. The different industries covered by our data encompass APIs, FDFs, pharma intermediates, paints, dyes, polymers, biotechnology, biochemical, food additives, nutraceuticals, etc.

2. How can I subscribe to the Chemxpert database?

You can gain access to the Chemxpert database after subscribing to it by visiting this link: - https://chemxpert.com/pricing

3. How many countries' data is available on your portal?

The Chemxpert database covers more than 200 countries. We are working in the direction of expanding our data coverage in more countries.

4. What are the different sources you use for obtaining information?

The different sources we use for data collection are as follows: - • Primary researc • DMF, ANDA, & CEP list • Conferences, Exhibitions, & Tradeshow • Company annual reports • DMF, ANDA, & CEP list • Subject matter experts & KOL survey. Apart from these, our other valuable sources include application-wise manufacturers list, subscribed and non-subscribed databases, corporate partners, US FDA Orange book, publicly available sources, industry associates, national statistics, regulatory websites, etc. You can gain access to the Chemxpert database after subscribing to it by visiting this link: -https://chemxpert.com/sources

5. What is the expected time for account activation?

Your Chemxpert account will be activated instantly if the payment is made through our website. If you choose to use RTGS, NEFT, or IMPS systems for payment, your account will be activated within 24 hours.

11 Dec 2025
Admin
News Article

Polpharma Biologics Partners with Libbs to Bring a New Autoimmune Biosimilar to Brazil

The Brazilian biosimilars market is accelerating fast. Demand is rising. Access gaps remain. And global innovators are looking for the right partners to scale in Latin America.
Polpharma Biologics has now taken a major step in that direction through a strategic collaboration with Libbs Farmacêutica.

A Partnership Built for Scale

Under this landmark agreement, Libbs Farmacêutica will receive exclusive rights to commercialize a next-generation autoimmune biosimilar in Brazil. Polpharma Biologics will continue to lead development and manufacturing, while Libbs manages commercialization, marketing, and distribution.

This division of strengths creates a powerful combination:

Polpharma Biologics: deep biologics development experience and global-scale manufacturing
Libbs: strong commercial reach and trusted presence across the Brazilian healthcare system

Together, they aim to expand access to advanced biological therapies for millions of patients.

Why This Deal Matters?

Brazil represents one of the fastest-growing autoimmune therapy markets. Yet access to biologics remains uneven due to cost and supply constraints.
A local–global partnership unlocks several advantages:

Faster market entry
Wider and more affordable access
Stronger regulatory execution for Anvisa submissions
Localized commercial strategies tailored to Brazil’s unique health ecosystem

The biosimilar is still in development and expected to be submitted for Anvisa approval within three years.

Leadership on Both Sides Welcomes the Move

Anjan Selz, CEO of Polpharma Biologics, emphasized the significance of entering Brazil with a biosimilar. He highlighted the mission to broaden availability of affordable biologics and recognized Libbs’ strong market expertise.

Libbs CEO, Alcebíades de Mendonça Athayde Junior, reinforced that the company already reaches over 15 million patients and continues to invest in a diversified, high-impact medicine portfolio. The partnership strengthens this mission.

Expanding Access Through Collaboration

For patients living with autoimmune diseases, this upcoming biosimilar promises:

A modern therapeutic option
Effective and well-tolerated treatment
Improved accessibility at a lower cost compared to originator biologics

And for both companies, the move strengthens their global positioning in the biosimilars space.

Let’s apply Data-Driven Pricing to Your APIs

Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.

Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.

Start using market intelligence today and allow yourself to be in control in the API market.

Check it out today and make more informed sourcing decisions! Learn More!